» Articles » PMID: 36292014

Classical Hodgkin Lymphoma: A Joint Clinical and PET Model to Predict Poor Responders at Interim Assessment

Overview
Specialty Radiology
Date 2022 Oct 27
PMID 36292014
Authors
Affiliations
Soon will be listed here.
Abstract

(1) This study aimed to investigate whether baseline clinical and Positron Emission Tomography/Computed Tomography (bPET)-derived parameters could help predicting early response to the first two cycles of chemotherapy (Deauville Score at interim PET, DS at iPET) in patients with classical Hodgkin lymphoma (cHL) to identify poor responders (DS ≥ 4) who could benefit from first-line treatment intensification at an earlier time point. (2) cHL patients with a bPET and an iPET imaging study in our Centre’s records (2013−2019), no synchronous/metachronous tumors, no major surgical resection of disease prior to bPET, and treated with two cycles of ABVD chemotherapy before iPET were retrospectively included. Baseline International Prognostic Score for HL (IPS) parameters were collected. Each patient’s bPET total metabolic tumor volume (TMTV) and highest tumoral SUVmax were collected. ROC curves and Youden’s index were used to derive the optimal thresholds of TMTV and SUVmax with regard to the DS (≥4). Chi-square or Fisher’s exact test were used for the univariate analysis. A multivariate analysis was then performed using logistic regression. The type I error rate in the hypothesis testing was set to 5%. (3) A total of 146 patients were included. The optimal threshold to predict a DS ≥ 4 was >177 mL for TMTV and >14.7 for SUVmax (AUC of 0.65 and 0.58, respectively). The univariate analysis showed that only TMTV, SUVmax, advanced disease stage, and age were significantly associated with a DS ≥ 4. A multivariate model was finally derived from TMTV, SUVmax, and age, with an AUC of 0.77. (4) A multivariate model with bPET parameters and age at diagnosis was satisfactorily predictive of poor response at iPET after ABVD induction chemotherapy in cHL patients. More studies are needed to validate these results and further implement DS-predictive factors at baseline in order to prevent poor response and intensify therapeutic strategies a-priori when needed.

Citing Articles

A different perspective on PET/CT before treatment in patients with Hodgkin lymphoma: importance of volumetric and dissemination parameters.

Aksu A, Kucuker K, Solmaz S, Turgut B Ann Hematol. 2023; 103(3):813-822.

PMID: 37964021 DOI: 10.1007/s00277-023-05547-1.


Baseline F-FDG PET/CT Radiomics in Classical Hodgkin's Lymphoma: The Predictive Role of the Largest and the Hottest Lesions.

Triumbari E, Gatta R, Maiolo E, De Summa M, Boldrini L, Mayerhoefer M Diagnostics (Basel). 2023; 13(8).

PMID: 37189492 PMC: 10137254. DOI: 10.3390/diagnostics13081391.

References
1.
Ben Bouallegue F, Al Tabaa Y, Kafrouni M, Cartron G, Vauchot F, Mariano-Goulart D . Association between textural and morphological tumor indices on baseline PET-CT and early metabolic response on interim PET-CT in bulky malignant lymphomas. Med Phys. 2017; 44(9):4608-4619. DOI: 10.1002/mp.12349. View

2.
Meignan M, Gallamini A, Haioun C . Report on the First International Workshop on Interim-PET-Scan in Lymphoma. Leuk Lymphoma. 2009; 50(8):1257-60. DOI: 10.1080/10428190903040048. View

3.
Cheson B, Fisher R, Barrington S, Cavalli F, Schwartz L, Zucca E . Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014; 32(27):3059-68. PMC: 4979083. DOI: 10.1200/JCO.2013.54.8800. View

4.
Milgrom S, Elhalawani H, Lee J, Wang Q, Mohamed A, Dabaja B . A PET Radiomics Model to Predict Refractory Mediastinal Hodgkin Lymphoma. Sci Rep. 2019; 9(1):1322. PMC: 6361903. DOI: 10.1038/s41598-018-37197-z. View

5.
Ucar E, Yalcin H, Kavvasoglu G, Ilhan G . Correlations between the Maximum Standard Uptake Value of Positron Emission Tomography/Computed Tomography and Laboratory Parameters before and after Treatment in Patients with Lymphoma. Chin Med J (Engl). 2018; 131(15):1776-1779. PMC: 6071459. DOI: 10.4103/0366-6999.237392. View